TURis plasma vaporization is a new surgical option for the treatment of benign prostatic hyperplasia (BPH) developed by Olympus. TURis constitutes an innovative development of TUR-P in which prostate tissue is removed safely and gently.
Hamburg, 09 September 2009. About one third of men over the age of 50 and half of those over 70 suffer from the effects of an enlarged prostate gland. From the age of 30, a man’s prostate can begin to enlarge as a natural process of aging whereby it increasingly presses on the urethra and thus narrows it. This can lead to the typical voiding disorders: a weak urine stream, dribbling after urination, feeling that the bladder is not completely empty and/or the need to pass urine frequently at night. This condition is called benign prostatic hyperplasia (BPH) and its symptoms can reduce the quality of life to a great extent. BPH also may cause complications such as severe urinary tract infections, urinary retention or even renal failure.
The TURis plasma vaporization electrode does not cut off tissue with a loop, but energetically vaporizes the tissue with a small button electrode. With the help of the latest plasma technology, cells can be removed by merely gliding the electrode over the prostate tissue. A smooth tissue surface is left behind – no healthy tissue is irritated or injured by plasma vaporization. Bleeds during and after this minimally invasive surgery can be avoided with this technique and quick healing of the wound stimulated. Plasma vaporization represents an innovative surgical treatment option that can remove the cause of BPH safely, gently and with high efficiency.
For physicians, this new procedure is very convenient. The learning curve is short: The TURis procedure is well established, thus electrode guidance skills can be acquired effortlessly and quickly. The semi-spherical design of the electrode allows the surgeon to guide it precisely over the tissue for highly targeted treatment. The view of the operation field remains clear because no tissue shavings, blood or laser impulses restrict the visual field.
For further information, please visit the website www.olympus-owi.com/plasmavaporization, or participate in the symposium "Plasma Vaporization & TURis: An update from long-term users” offered by Olympus at the World Congress of Endourology (WCE) in Munich, October 9, 2009, from 4pm to 5:30pm in Hall Asam 1.
1 April: André Roggan to become new Managing Director of Olympus Surgical Technologies Europe
13 October: Olympus Surgical introduces all-in-one system for safe and comfortable hysteroscopy
1 April 2011: Hamburg-based Olympus Surgical Group celebrates first anniversary with takeover of fifth company
1 April 2011: Olympus Surgical UK becomes fifth member of the Olympus Surgical Group based in Hamburg
1 January 2011: Gyrus Medical GmbH under the umbrella brand of Olympus Surgical Technologies Europe
26 November 2010: Olympus Surgical honoured at Manufacturing Excellence Award 2010
22 September 2010: Two years of training for doctors in the Olympus Medical Training Centre
28 June 2010: Ergonomics through product design
1 April 2010: Olympus Winter & Ibe GmbH forms group of companies under a single roof: Olympus Surgical Technologies Europe
24 November 2009: Olympus opens technology centre for medical energy products
19 October 2009: Olympus is one of the first suppliers to offer a complete set for the innovative minimally invasive operating technique LESS Surgery
9 September 2009: TURis plasma vaporization electrode from Olympus revolutionises the therapy of benign prostatic hyperplasia
5 May 2009: A convincing demonstration of LESS surgery: Minimally invasive operations with Olympus equipment honoured by American Urological Association
11 December 2008: Olympus further enhances credentials by entering into exclusive sales and distribution partnership
29 October 2008: Visit to the world's most modern training centre for endoscopic systems as part of the German-Arab Health Forum
26 September 2008: New plasma vaporization electrode combines maximum effectiveness with lowest possible side effects